ESRRA and breast carcinoma: This evidence prompted us to speculate that cholesterol and its biosynthetic precursor, mevalonate, can drive aggressiveness and resistance to anti-cancer therapy used for breast cancer treatment, through the activation of ERRα and related pathways.